Zhao and Burgess [107] reported the first CDK4/6 PROTAC compound (Figure 7A) based on cereblon recruiter (pomalidomide) that was active against the MDA-MB-231 breast cancer cell line in the nanomolar range and reduced the pRB level. Here, CDK4 is linked to breast carcinoma.